Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Wilcock, Gordon; Gauthier, Serge; B. Frisoni, Giovanni; Jia, Jianping; Hardlund, Jiri; J. Moebius, Hans; Bentham, Peter; A. Kook, Karin; Schelter, B.; Wischik, Damon; S. Davis, Charles; T. Staff, Roger; Vuksanović, Vesna; Ahearn, Trevor; Bracoud, Luc; Shamsi, Kohkan; Marek, Kenneth; Seibyl, John; Riedel, Gernot; M. D. Storey, John; R. Harrington, Charles; M. Wischik, Claude

doi:10.3233/jad-170560

Public

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Published in Journal of Alzheimer s Disease • Nov 17, 2017

Authors:

Gordon Wilcock

Serge Gauthier

Giovanni B. Frisoni

Abstract

BACKGROUND: LMTM is being developed as a treatment for AD based on inhibition of tau aggregation. OBJECTIVES: To examine the efficacy of LMTM as monotherapy in non-randomized cohort analyses as modified primary outcomes in an 18-month Phase III trial in mild AD. METHODS: Mild AD patients (n = 800) w...

Subject

Medicine

Internal medicine

Randomized controlled trial

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!